This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Ecstasy

Authoring team

  • ecstasy - name given by its users to 3,4-methylene-dioxymethamphetamine (MDMA)
    • second most commonly used controlled drug (after cannabis) in Europe
    • MDMA is a ring-substituted amphetamine derivative
    • related to the hallucinogenic compound mescaline
      • does not produce the profound sensory disruptions or hallucinations associated with classical hallucinogens such as lysergic acid diethylamine (LSD)e
      • increases emotional sensitivity and empathy
        • also MDMA use associated with a loss of inhibitions; reduced anxiety; increased sense of closeness with other people
  • pharmacology
    • action in the central nervous system is complex
      • major effects on serotonin (5-hydroxytryptamine [5-HT]) pathways - however also affects two other major transmitter systems in the brain: dopamine (DA) and noradrenaline
      • use of MDMA causes an acute and rapid increase in extracellular 5-HT
        • causes a marked depletion of 5-HT from brain tissue in the first few hours following drug administration
      • in rat models 5-HT levels recover within 24 h after a single dose of MDMA; however higher doses of MDMA can result in sustained depletion of 5-HT that can last for up to 12 months
        • MDMA also blocks the activity of tryptophan hydroxylase (rate-limiting enzyme in the biosynthesis of 5-HT)
          • this effect occurs within 15 min following administration - can last for up to two weeks
  • acute toxic effects
    • malignant hyperthermia - this syndrome of persistent hyperthermia which leads to the rhabdomyolysis with subsequent renal and other organ failure
      • mechanism for this is unknown - there may be a possible role for uncoupling protein-3, a mitochondrial protein known to play a role in thermogenesis
  • neuropsychological effects of depletion of brain levels of 5-HT
    • following MDMA use
      • subjective effects reported are euphoria, changes in perception (sound and light), a reduction in defensiveness (negative affect), emotional openness, empathy and a reduction of inhibitions
        • effects are likely to be mediated via the 5-HT-system
        • the use of ectasy does not leave the user with a "neutral" mood
          • following ecstasy use there is an ‘offset’ period - during this period there is a worsening of mood - this low mood persists for several days (known as the ‘midweek blues’)
          • it has been suggested that there may be an increase in aggression/anger/anxiety occurs after taking ecstasy - tends to peak four days after taking the drug
          • effects of ecstasy on mood appear to be reversible
          • there is study evidence that indicate that depression, impulsivity, and sensation seeking do not predict first time ecstasy use in a population of young adults with the intention to start using ecstasy (2)
  • there is evidence from studies of long term MDMA use of long-term (weeks to months) impairments in memory and learning; in particular, working memory, planning ability, executive control and cognitive impulsivity

The effects of ecstasy on the cardiovascular system are described in the linked item.

Notes:

  • a study investigating the safety of single or low dose of ecstasy has been undertaken (3):
    • the study showed no differences in metabolites concentrations before and after ecstasy use and found no indications for major neuronal damage after a single or low dose of ecstasy use in first time ecstasy users. Howeve the authors stated that, because there might be various factors that play a role in individual vulnerability for acute and long-term effects of ecstasy, it is not possible to state that the use of a single or low dose of ecstasy is totally safe

Reference:

  1. Curr Opin Pharmacol. 2005 Feb;5(1):79-86
  2. J Psychopharmacol. 2006 Mar;20(2):226-35.
  3. Europ Neuropsychopharm 2006; 16(1): S79-S80.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.